Suganthini Krishnan-Natesan

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. ncbi In vitro-in vivo correlation of voriconazole resistance due to G448S mutation (cyp51A gene) in Aspergillus fumigatus
    S Krishnan Natesan
    John D Dingell VA Medical Center, Detroit, MI, USA
    Diagn Microbiol Infect Dis 74:272-7. 2012
  2. ncbi In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus
    Suganthini Krishnan-Natesan
    Wayne State University, Detroit, MI, USA
    Diagn Microbiol Infect Dis 73:135-7. 2012
  3. ncbi Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model
    Suganthini Krishnan-Natesan
    Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI 48201, USA
    Int J Antimicrob Agents 36:33-6. 2010
  4. ncbi Terbinafine: a pharmacological and clinical review
    S Krishnan-Natesan
    Wayne State University John D Dingell VA Medical Center, Medicine Infectious Diseases, 3990 John R, 5 Hudson, Detroit, MI 48201, USA
    Expert Opin Pharmacother 10:2723-33. 2009
  5. ncbi A comparison of the fungicidal activity of amphotericin B and posaconazole against Zygomycetes in vitro
    Suganthini Krishnan-Natesan
    Department of Medicine, Division of Infectious Diseases, Wayne State University, John D Dingell VA Medical Center, Detroit, MI, USA
    Diagn Microbiol Infect Dis 63:361-4. 2009
  6. ncbi Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance
    Suganthini Krishnan
    Division of Infectious Diseases, Wayne State University, John D Dingell VA Medical Center, Detroit, MI 48201, USA
    Mycoses 52:206-22. 2009
  7. ncbi Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine
    Suganthini Krishnan-Natesan
    Wayne State University, Detroit, MI 48202, USA
    Diagn Microbiol Infect Dis 62:443-6. 2008
  8. ncbi Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus
    Suganthini Krishnan-Natesan
    Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI 48201, USA
    Int J Antimicrob Agents 32:519-24. 2008
  9. ncbi Current and future therapeutic options in the management of invasive aspergillosis
    Suganthini Krishnan-Natesan
    Department of Internal Medicine, Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, Michigan, USA
    Drugs 68:265-82. 2008
  10. ncbi Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro
    Suganthini Krishnan Natesan
    Department of Internal Medicine Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Diagn Microbiol Infect Dis 60:369-73. 2008

Collaborators

Detail Information

Publications10

  1. ncbi In vitro-in vivo correlation of voriconazole resistance due to G448S mutation (cyp51A gene) in Aspergillus fumigatus
    S Krishnan Natesan
    John D Dingell VA Medical Center, Detroit, MI, USA
    Diagn Microbiol Infect Dis 74:272-7. 2012
    ..fumigatus. Our study demonstrated that azole resistance is based on specific site of cyp51A mutation and that in vitro VRC-R correlates with in vivo resistance...
  2. ncbi In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus
    Suganthini Krishnan-Natesan
    Wayne State University, Detroit, MI, USA
    Diagn Microbiol Infect Dis 73:135-7. 2012
    ..5) not only against VCZ-susceptible isolates, but also against 8 of 10 VCZ-R, G448S mutants of A. fumigatus. The combination demonstrated synergy against the VCZ-R clinical isolate as well...
  3. ncbi Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model
    Suganthini Krishnan-Natesan
    Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI 48201, USA
    Int J Antimicrob Agents 36:33-6. 2010
    ..Thus, echinocandins have excellent antifungal activity in the early phase of disseminated Candida albicans infection and may contribute to an improved outcome in critically ill immunocompromised/neutropenic patients...
  4. ncbi Terbinafine: a pharmacological and clinical review
    S Krishnan-Natesan
    Wayne State University John D Dingell VA Medical Center, Medicine Infectious Diseases, 3990 John R, 5 Hudson, Detroit, MI 48201, USA
    Expert Opin Pharmacother 10:2723-33. 2009
    ....
  5. ncbi A comparison of the fungicidal activity of amphotericin B and posaconazole against Zygomycetes in vitro
    Suganthini Krishnan-Natesan
    Department of Medicine, Division of Infectious Diseases, Wayne State University, John D Dingell VA Medical Center, Detroit, MI, USA
    Diagn Microbiol Infect Dis 63:361-4. 2009
    ....
  6. ncbi Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance
    Suganthini Krishnan
    Division of Infectious Diseases, Wayne State University, John D Dingell VA Medical Center, Detroit, MI 48201, USA
    Mycoses 52:206-22. 2009
    ..flavus in the literature. This article reviews the microbiology, toxigenicity and epidemiology of A. flavus as well as describes the clinical characteristics, diagnosis and management of infections caused by this organism...
  7. ncbi Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine
    Suganthini Krishnan-Natesan
    Wayne State University, Detroit, MI 48202, USA
    Diagn Microbiol Infect Dis 62:443-6. 2008
    ..Combination of VRC with TBF showed synergistic activity (FICI = 0.5). Therefore, combination of VRC and TBF with surgical debridement, when appropriate, may be a viable treatment option for refractory A. ustus infections...
  8. ncbi Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus
    Suganthini Krishnan-Natesan
    Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI 48201, USA
    Int J Antimicrob Agents 32:519-24. 2008
    ..flavus isolates can be readily isolated in the laboratory under selection pressure. Multiple mechanisms, including drug target modification, may be responsible for the in vitro resistance of A. flavus to VCZ...
  9. ncbi Current and future therapeutic options in the management of invasive aspergillosis
    Suganthini Krishnan-Natesan
    Department of Internal Medicine, Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, Michigan, USA
    Drugs 68:265-82. 2008
    ..The promise of newer classes of drugs, immune-modulating therapies and vaccines are exciting future additions to the arsenal against invasive aspergillosis...
  10. ncbi Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro
    Suganthini Krishnan Natesan
    Department of Internal Medicine Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Diagn Microbiol Infect Dis 60:369-73. 2008
    ..9% killing of A. fumigatus conidia, whereas either drug alone showed poor activity at subinhibitory concentrations. FST potentiated the antifungal activity of CFG but displayed no specific interaction with voriconazole or amphotericin B...